ProCE Banner Activity

Harnessing HBV and HDV Screening for Earlier Diagnosis

Clinical Thought

Rates of hepatitis B virus (HBV) and hepatitis delta virus (HDV) testing remain suboptimal compared with the estimated real-world prevalence of infections. Read expert perspectives on how to implement best practices for HBV and HDV screening for earlier diagnosis.

Released: January 05, 2024

Share

Faculty

Douglas Dieterich

Douglas Dieterich, MD

Director, Institute for Liver Medicine
Professor of Medicine
Division of Liver Diseases
New York, New York

Camilla S. Graham

Camilla S. Graham, MD, MPH

Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Robert Wong

Robert Wong, MD, MS, FACG

Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC, in partnership with Hepatitis B Foundation.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Hepatitis B Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Douglas Dieterich, MD

Director, Institute for Liver Medicine
Professor of Medicine
Division of Liver Diseases
New York, New York

Douglas Dieterich, MD: consultant/advisor/speaker: Gilead, Intercept.

Camilla S. Graham, MD, MPH

Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Camilla S. Graham, MD, MPH, has no relevant financial relationships to disclose.

Robert Wong, MD, MS, FACG

Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California

Robert Wong, MD, MS: researcher: Durect Corporation, Exact Sciences, Gilead, Theratechnologies.